Literature DB >> 7517170

Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

M Mohrmann1, S Ansorge, U Schmich, B Schönfeld, M Brandis.   

Abstract

Ifosfamide (IF) and cyclophosphamide (CP) are highly effective alkylating cytostatic drugs. IF and CP have to be activated through a metabolic step in vivo; numerous metabolites are known. While both IF and its structural isomer CP have severe urotoxic side effects, only IF is also a nephrotoxic drug, causing tubular damage resulting in Fanconi syndrome in some cases. Little information is available regarding the pathogenic mechanism of tubular damage by IF. We used the renal epithelial cell line LLC-PK1, which has many properties of the proximal tubule, in order to investigate the toxicity of IF and CP and of their reactive metabolites 4-hydroxy-IF (4-OH-IF), 4-hydroxy-CP (4-OH-CP), acrolein and chloroacetaldehyde (CAA). Protein content of monolayers, DNA and RNA synthesis were determined by standard techniques (thymidine and uridine incorporation). IF and CP had the lowest toxicities of all compounds tested. Both drugs inhibited thymidine incorporation by about 30% at a concentration of 300 mumol/l after 1 h incubation. 4-OH-IF and 4-OH-CP were significantly more toxic than the parent drugs. Thymidine incorporation, the most sensitive parameter, was reduced by about 70% by 300 mumol/l of either compound. In addition, 4-OH-CP reduced the total protein content of monolayers. 4-OH-IF did not effect protein content and RNA synthesis. Acrolein, the most toxic metabolite tested, reduced all three parameters significantly at concentrations of 50-75 mumol/l after 1 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517170     DOI: 10.1007/bf00865466

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  49 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.

Authors:  A Suarez; H McDowell; P Niaudet; E Comoy; F Flamant
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 44.544

Review 3.  Mesna--a short review.

Authors:  I C Shaw; M I Graham
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

4.  Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.

Authors:  R Pearcey; R Calvert; A Mehta
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.

Authors:  H Jürgens; U Exner; J Kühl; J Ritter; J Treuner; P Weinel; K Winkler; U Göbel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.

Authors:  I Magrath; J Sandlund; A Raynor; S Rosenberg; V Arasi; J Miser
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Sodium-dependent transport of phosphate in LLC-PK1 cells.

Authors:  J Biber; C D Brown; H Murer
Journal:  Biochim Biophys Acta       Date:  1983-11-23

8.  Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture.

Authors:  M Mohrmann; A Pauli; H Walkenhorst; B Schönfeld; M Brandis
Journal:  Ren Physiol Biochem       Date:  1993 Nov-Dec

9.  Acrolein and cell cycle.

Authors:  F Marano; S Puiseux-Dao
Journal:  Toxicol Lett       Date:  1982-12       Impact factor: 4.372

10.  Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

Authors:  M P Goren; R K Wright; M E Horowitz; C B Pratt
Journal:  Cancer Treat Rep       Date:  1987-02
View more
  10 in total

1.  Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro- and nephrotoxicities by modulating antioxidant status and pro-inflammatory cytokine levels.

Authors:  T P Hamsa; Girija Kuttan
Journal:  Inflammopharmacology       Date:  2010-09-29       Impact factor: 4.473

2.  Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.

Authors:  J Springate; K Chan; H Lu; S Davies; M Taub
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-06       Impact factor: 2.416

3.  Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Nader Gordjani; Andreas Benesic; Ruth Freudinger; Brigitte Wollny; Antje Kirchhoff; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2005-11-03       Impact factor: 3.714

4.  The effects and the toxicity increases caused by bicarbonate, chloride, and other water components during the UV/TiO2 degradation of oxazaphosphorine drugs.

Authors:  Webber Wei-Po Lai; Ying-Chih Chuang; Angela Yu-Chen Lin
Journal:  Environ Sci Pollut Res Int       Date:  2017-04-27       Impact factor: 4.223

5.  Renal tubular dysfunction in children with systemic lupus erythematosus.

Authors:  Stephen D Marks; Vanita Shah; Clarissa Pilkington; Patricia Woo; Michael J Dillon
Journal:  Pediatr Nephrol       Date:  2004-12-28       Impact factor: 3.714

6.  Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.

Authors:  Hiroaki Nishimura; Hideki Enokida; Satoshi Nagano; Masahiro Yokouchi; Hiroshi Hayami; Setsuro Komiya; Masayuki Nakagawa
Journal:  J Artif Organs       Date:  2013-10-04       Impact factor: 1.731

7.  Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide.

Authors:  Premila Abraham; Suganthy Rabi
Journal:  Clin Exp Nephrol       Date:  2009-03-07       Impact factor: 2.801

8.  Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.

Authors:  M Mohrmann; S Ansorge; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

9.  Osteomalacia as a late metabolic complication of Ifosfamide chemotherapy in young adults: illustrative cases and review of the literature.

Authors:  D N Church; A B Hassan; S J Harper; C J Wakeley; C G A Price
Journal:  Sarcoma       Date:  2007

10.  Beneficial Effects of Bioactive Compounds in Mulberry Fruits against Cisplatin-Induced Nephrotoxicity.

Authors:  Dahae Lee; Jae Sik Yu; Seoung Rak Lee; Gwi Seo Hwang; Ki Sung Kang; Jae Gyu Park; Hyun Young Kim; Ki Hyun Kim; Noriko Yamabe
Journal:  Int J Mol Sci       Date:  2018-04-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.